Kyverna Therapeutics (Kyverna Therapeutics) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Change In Receivables?

Kyverna Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Kyverna Therapeutics's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Kyverna Therapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Kyverna Therapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Kyverna Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Kyverna Therapeutics's liquidation value for the three months ended in Mar. 2024 was $340.80 Mil.

Kyverna Therapeutics Change In Receivables Historical Data

The historical data trend for Kyverna Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Change In Receivables Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Change In Receivables

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial			-	-	-	-	-

Kyverna Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Kyverna Therapeutics (NAS:KYTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Kyverna Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Kyverna Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Kyverna Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	369.794	-	28.993	+	0.75 * 0	+	0.5 * 0
=	340.80

Kyverna Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024